Skip to main content

Antiphospholipid Antibodies and Atherosclerosis: Insights from Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome

Clinical Reviews in Allergy & Immunology volume 37, pages 29–35 (2009)Cite this article

Abstract

The issue of atherosclerosis in the antiphospholipid syndrome (APS) is receiving considerable attention within and without the autoimmune settting. Measurement of arterial intima media thickness (IMT) of is an easy and surrogate means of detecting subclinical atherosclerosis. This technique has been applied to patients with systemic lupus erythematosus (SLE) nand primary APS in the attempt to unravel a possible association between antiphospholipid antibodies and premature atherosclerosis. The available data is reviewed in the light of the most recent atherogenic pathways that may differentially account for premature vascular disease in SLE and primary APS.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Ross R (1999) Atherosclerosis: an inflammatory disease. N Engl J Med 340:115–126

    PubMed  Article  CAS  Google Scholar 

  2. Hahn BH, Grossman J, Chen W, McMahon M (2007) The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 28:69–75

    PubMed  Article  CAS  Google Scholar 

  3. Cervera R, Khamashta MA, Font J et al (1999) Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine 78:167–175

    PubMed  Article  CAS  Google Scholar 

  4. Cervera R, Piette JC, Font J et al (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019–1027

    PubMed  Article  Google Scholar 

  5. Touboul PJ, Labreuche J, Vicaut E et al (2005) Carotid Intima-Media Thickness, Plaques, and Framingham Risk Score as Independent Determinants of Stroke Risk. Stroke 36:1741–1745

    PubMed  Article  Google Scholar 

  6. Manzi S, Selzer F, Sutton-Tyrrell K et al (1999) Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 42:51–60

    PubMed  Article  CAS  Google Scholar 

  7. Roman MJ, Shanker BA, Davis A et al (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349:2399–2406

    PubMed  Article  CAS  Google Scholar 

  8. Svenungsson E, Jensen-Urstad K, Heimbürger M et al (2001) Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104:1887

    PubMed  Article  CAS  Google Scholar 

  9. Jiménez S, García-Criado MA, Tàssies D et al (2005) Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology 44:756–761

    PubMed  Article  Google Scholar 

  10. Sato H, Miida T, Wada Y et al (2007) Atherosclerosis is accelerated in patients with long-term well-controlled systemic lupus erythematosus (SLE). Clin Chim Acta 385:35–42

    PubMed  Article  CAS  Google Scholar 

  11. Vlachoyiannopoulos PG, Kanellopoulos PG, Ioannidis JP, Tektonidou MG, Mastorakou I, Moutsopoulos HM (2003) Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. Rheumatology 42:645–651

    PubMed  Article  CAS  Google Scholar 

  12. Falaschi F, Ravelli A, Martignoni A et al (2000) Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum 43:1405–1409

    PubMed  Article  CAS  Google Scholar 

  13. Rossi M, Mosca M, Tani C, Franzoni F, Santoro G, Bombardieri S (2008) Integrated backscatter analysis of carotid intima–media complex in patients with systemic lupus erythematosus. Clin Rheumatol (in press)

  14. de Leeuw K, Freire B, Smit AJ, Bootsma H, Kallenberg CG, Bijl M (2006) Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus 15:675–682

    PubMed  Article  Google Scholar 

  15. Wolak T, Todosoui E, Szendro G et al (2004) Duplex study of the carotid and femoral arteries of patients with systemic lupus erythematosus: a controlled study. J Rheumatol 31:909–914

    PubMed  Google Scholar 

  16. Bowser CS, Kumar S, Salciccioli L et al (2008) Absence of Chlamydia pneumoniae and signs of atherosclerotic cardiovascular disease in adolescents with systemic lupus erythematosus. Pediatr Cardiol 29:545–551

    PubMed  Article  Google Scholar 

  17. Roman MJ, Crow MK, Lockshin MD et al (2007) Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 56:3412–3419

    PubMed  Article  CAS  Google Scholar 

  18. Thompson T, Sutton-Tyrrell K, Wildman RP et al (2008) Progression of carotid intima–media thickness and plaque in women with systemic lupus erythematosus. Arthritis Rheum 58:835–842

    PubMed  Article  CAS  Google Scholar 

  19. Bilora F, Boccioletti V, Girolami B et al (2002) Are antiphospholipid antibodies an independent risk factor for atherosclerosis? Clin Appl Thromb Hemost 8:103–113

    PubMed  Article  Google Scholar 

  20. Medina G, Casaos D, Jara LJ et al (2003) Increased carotid artery intima–media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann Rheum Dis 62:607–610

    PubMed  Article  CAS  Google Scholar 

  21. Der H, Kerekes G, Veres K et al (2007) Impaired endothelial function and increased carotid intima–media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome. Lupus 16:497–503

    PubMed  Article  CAS  Google Scholar 

  22. Margarita A, Batuca J, Scenna J et al (2007) Subclinical atherosclerosis in primary antiphospholipid syndrome. Ann N Y Acad Sci 1108:475–480

    PubMed  Article  CAS  Google Scholar 

  23. Ames PRJ, Margarita A, Delgado Alves J, Tommasino C, Iannaccone L, Brancaccio V (2002) Anticardiolipin antibody titre and plasma homocysteine levels independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus 11:208–214

    PubMed  Article  CAS  Google Scholar 

  24. Belizna CC, Richard V, Primard E et al (2008) Early atheroma in primary and secondary antiphospholipid syndrome: an intrinsic finding. Semin Arthritis Rheum 37:373–380

    PubMed  Article  Google Scholar 

  25. Alarcon-Segovia D, Cardiel MH, Reyes E (1989) Antiphospholipid arterial vasculopathy. J Rheumatol 16:762–767

    PubMed  CAS  Google Scholar 

  26. Lie JT (1989) Vasculopathy in the antiphospholipid syndrome: thrombosis or vasculitis, or both? J Rheumatol 16:713–715

    PubMed  CAS  Google Scholar 

  27. Taylor LM Jr, Chitwood RW, Dalman RL, Sexton G, Goodnight SH, Porter JM (1994) Antiphospholipid antibodies in vascular surgery patients. A cross-sectional study. Ann Surg 220:544–551

    PubMed  Article  Google Scholar 

  28. Nityanand S, Bergmark C, de Faire U, Swedenborg J, Holm G, Lefvert AK (1995) Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease. J Intern Med 238:437–443

    PubMed  CAS  Article  Google Scholar 

  29. Friehs I, Eber B, Friehs G, Langsteger W, Koch G (1992) IgG-anticardiolipin-antibodies are markers for cerebral and peripheral artery disease. Vasa 21:158–162

    PubMed  CAS  Google Scholar 

  30. Fligelstone LJ, Cachia PG, Ralis H et al (1995) Lupus anticoagulant in patients with peripheral vascular disease: a prospective study. Eur J Vasc Endovasc Surg 9:277–283

    PubMed  Article  CAS  Google Scholar 

  31. Vig S, Chitolie A, Bevan D, Dormandy J, Thompson MM, Halliday A (2006) The prevalence of thrombophilia in patients with symptomatic peripheral vascular disease. Br J Surg 93:577–581

    PubMed  Article  CAS  Google Scholar 

  32. Durga J, Verhoef P, Bots ML, Schouten E (2004) Homocysteine and carotid intima–media thickness: a critical appraisal of the evidence. Atherosclerosis 176:1–19

    PubMed  Article  CAS  Google Scholar 

  33. Voutilainen S, Morrow JD, Roberts LJ 2nd et al (1999) Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels. Arterioscler Thromb Vasc Biol 19:1263–1266

    PubMed  CAS  Google Scholar 

  34. Rodrigo R, Prat H, Passalacqua W, Araya J, Guichard C, Bächler JP (2007) Relationship between oxidative stress and essential hypertension. Hypertens Res 30:1159–1167

    PubMed  Article  CAS  Google Scholar 

  35. Negre-Salvayre A, Dousset N, Ferretti G, Bacchetti T, Curatola G, Salvayre R (2006) Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radic Biol Med 41:1031–1040

    PubMed  Article  CAS  Google Scholar 

  36. Mackness MI, Arrol S, Durrington PN (1991) Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286:152–154

    PubMed  Article  CAS  Google Scholar 

  37. Nourooz-Zadeh J, Cooper MB, Ziegler D, Betteridge DJ (2005) Urinary 8-epi-PGF2alpha and its endogenous beta-oxidation products (2,3-dinor and 2,3-dinor-5,6-dihydro) as biomarkers of total body oxidative stress. Biochem Biophys Res Commun 330:731–736

    PubMed  Article  CAS  Google Scholar 

  38. Thomson MJ, Puntmann V, Kaski JC (2007) Atherosclerosis and oxidant stress: the end of the road for antioxidant vitamin treatment ? Cardiovasc Drugs Ther 21:195–210

    PubMed  Article  CAS  Google Scholar 

  39. Gloire G, Legrand-Poels S, Piette J (2006) NF-kappa B activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 72(11):1493–505 (Nov 30)

    PubMed  Article  CAS  Google Scholar 

  40. Delgado Alves J, Ames PR, Donohue S et al (2002) Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 46:2686–2694

    PubMed  Article  CAS  Google Scholar 

  41. Martinuzzo ME, Forastiero RR, Kordich L, Carreras LO (2001) Increased lipid peroxidation correlates with platelet activation but not with markers of endothelial cell and blood coagulation activation in patients with antiphospholipid antibodies. Br J Haematol 114:845–851

    PubMed  Article  CAS  Google Scholar 

  42. Galle J, Hansen-Hagge T, Wanner C, Seibold S (2006) Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis 185:219–226

    PubMed  Article  CAS  Google Scholar 

  43. Fong LG, Parthasarathy S, Witztum JL et al (1987) Nonenzymatic oxidative cleavage of peptide bonds in apoprotein B-100. J Lipid Res 28:1466–1477

    PubMed  CAS  Google Scholar 

  44. Esterbauer H, Jurgens G, Quehenberger O et al (1987) Autoxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. J Lipid Res 28:495–509

    PubMed  CAS  Google Scholar 

  45. Kobayashi K, Kishi M, Atsumi T et al (2003) Circulating oxidized LDL forms complexes with 2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res 44:716–726

    PubMed  Article  CAS  Google Scholar 

  46. Hasunuma Y, Matsuura E, Makita Z et al (1997) Involvement of b2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 107:569–573

    PubMed  Article  CAS  Google Scholar 

  47. Kobayashi K, Matsuura E, Liu Q et al (2001) A specific ligand for b2–19 glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J Lipid Res 42:697–709

    PubMed  CAS  Google Scholar 

  48. Merrill JT, Zhang HW, Shen C et al (1999) Enhancement of protein S anticoagulant function by b2-glycoprotein I, a major target antigen of antiphospholipid antibodies: b2-glycoprotein I interferes with binding of Protein S to its plasma inhibitor, C4b-binding protein. Thromb Haemost 81:748–757

    PubMed  CAS  Google Scholar 

  49. Balasubramanian K, Maiti SN, Schroit AJ (2005) Recruitment of beta-2-glycoprotein 1 to cell surfaces in extrinsic and intrinsic apoptosis. Apoptosis 10:439–446

    PubMed  Article  CAS  Google Scholar 

  50. Tsimikas S (2006) Oxidized low-density lipoprotein biomarkers in atherosclerosis. Curr Atheroscler Rep 8:55–61

    PubMed  Article  Google Scholar 

  51. Ames PRJ, Delgado Alves J, Lopez LR et al (2006) Antibodies against beta2-glycoprotein I complexed with an oxidised lipoprotein relate to intima thickening of carotid arteries in primary antiphospholipid syndrome. Clin Dev Immunol 13:1–9

    PubMed  Article  CAS  Google Scholar 

  52. Brown MS, Goldstein JL (1985) Scavenger cell receptor shared. Nature 316:680–681

    PubMed  Article  CAS  Google Scholar 

  53. Yamamoto T, Davis CG, Brown MS et al (1984) The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell 39:27–38

    PubMed  Article  CAS  Google Scholar 

  54. Ramprasad MP, Fischer W, Witztum JL et al (1995) The 94- to 97-kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and phosphatidylserine-rich liposomes is identical to macrosialin, the mouse homologue of human CD68. Proc Natl Acad Sci USA 92:9580–9584

    PubMed  Article  CAS  Google Scholar 

  55. Rigotti A, Acton SL, Krieger M (1995) The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids. J Biol Chem 270:16221–16224

    PubMed  Article  CAS  Google Scholar 

  56. Sorenson RC, Bisgaier CL, Aviram M et al (1999) Human serum paraoxonase/arylesterase’s retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol 19:2214–2225

    PubMed  CAS  Google Scholar 

  57. Khuseyinova N, Koenig W (2006) Apolipoprotein A-I and risk for cardiovascular diseases. Curr Atheroscler Rep 8(5):365–373 (Sep)

    PubMed  Article  CAS  Google Scholar 

  58. Batuca JR, Ames PRJ, Amaral M, Favas C, Isenberg DA, Delgado Alves J (2008) Anti-atherogenic and anti-inflammatory properties of high density lipoprotein are affected by specific antibodies in systemic lupus erythematosus. Rheumatology (in press)

  59. Ritis K, Doumas M, Mastellos D et al (2006) A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol 177:4794–4802

    PubMed  CAS  Google Scholar 

  60. Ramos-Casals M, Campoamor MT, Chamorro A et al (2004) Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients. Lupus 13:777–783

    PubMed  Article  CAS  Google Scholar 

  61. Redecha P, Tilley R, Tencati M et al (2007) Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody-induced fetal injury. Blood 110:2423–2431

    PubMed  Article  CAS  Google Scholar 

  62. Ames PRJ, Batuca J, Delgado Alves J et al (2008) Primary antiphospholipid syndrome: a low-grade auto-inflammatory disorder? Rheumatology (in press)

  63. Jackson M, Ahmad Y, Bruce IN, Coupes B, Brenchley PE (2006) Activation of transforming growth factor-beta1 and early atherosclerosis in systemic lupus erythematosus. Arthritis Res Ther 8:R81

    PubMed  Article  CAS  Google Scholar 

  64. Greenwood J, Mason JC (2007) Statins and the vascular endothelial inflammatory response. Trends Immunol 28:88–98

    PubMed  Article  CAS  Google Scholar 

  65. Ames PRJ, Tommasino C, Alves J et al (2000) Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: a pilot study. Lupus 9:688–695

    PubMed  Article  CAS  Google Scholar 

  66. Rubenstein E, Arkfeld DG, Metyas S, Shinada S, Ehresmann S, Liebman HA (2006) Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol 33:355–357

    PubMed  Google Scholar 

  67. Trappe R, Loew A, Thuss-Patience P, Dorken B, Riess H (2006) Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab-monitoring of antiphospholipid and anti-GP antibodies: a case report. Ann Hematol 85(2):134–135 (Feb)

    PubMed  Article  CAS  Google Scholar 

  68. Ames PR, Tommasino C, Fossati G, Scenna G, Brancaccio V, Ferrara F (2007) Limited effect of rituximab on thrombocytopaenia and anticardiolipin antibodies in a patient with primary antiphospholipid syndrome. Ann Hematol 86(3):227–228 (Mar)

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Haematology, Royal Preston Hospital, Preston, UK

    Paul R. J. Ames

  2. Angiology Unit, Antonio Cardarelli Hospital, Naples, Italy

    Annamaria Margarita

  3. Department of Pharmacology, New University of Lisbon, Lisbon, Portugal

    Jose Delgado Alves

Authors
  1. Paul R. J. Ames
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annamaria Margarita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jose Delgado Alves
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul R. J. Ames.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ames, P.R.J., Margarita, A. & Alves, J.D. Antiphospholipid Antibodies and Atherosclerosis: Insights from Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome. Clinic Rev Allerg Immunol 37, 29–35 (2009). https://doi.org/10.1007/s12016-008-8099-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-008-8099-5

Keywords

  • Antiphospholipid antibodies
  • Atherosclerosis
  • Systemic lupus erythematosus
  • Primary antiphospholipid syndrome